Renting Rubin : AstraZeneca IV – The Settlement Cost More Than The Company
The AstraZeneca Lynparza settlement reached $220 million after the University of Sheffield alleged that amendments to its patent licence had
Renting Rubin is TCAP’s ongoing examination of the public corporate records behind the prestige names in Daniel Rubin’s Horsfield Menzies biography. The series follows the documented controversies, investigations, regulatory findings, litigation and accountability failures of businesses including Barclays, BT and AstraZeneca.
The AstraZeneca Lynparza settlement reached $220 million after the University of Sheffield alleged that amendments to its patent licence had
The Barclays motor finance commission model gave a car dealer power to select the customer’s interest rate from a wide
BT celebrated record Openreach fibre connections, a 40% take-up rate and broadband revenue per user rising 7%. Five days later,
The first AstraZeneca instalment examined its reputation-management placebo. Part II followed the company’s “patients first” rhetoric to the public purse.
The Barclays Qatar capital raising sold independence from government money. Meanwhile, £322 million sat behind advisory agreements the FCA later
BT AI job cuts are usually presented as the unavoidable price of progress. The machines improve. The network modernises. Human
AstraZeneca drug pricing is where the company’s patient-first poetry meets somebody holding a calculator. The poetry does not survive. Part
The Barclays whistleblower hunt revealed a bank with extraordinary eyesight whenever the danger was an anonymous critic. Public registers, police
One hundred days ago, TCAP took its first birthday victory lap. I promised a surgical summer. Since then, 161 more